Carborane bearing pullulan nanogel-boron oxide nanoparticle hybrid for boron neutron capture therapy

Boron neutron capture therapy shows is a promising approach to cancer therapy, but the delivery of effective boron agents is challenging. To address the requirements for efficient boron delivery, we used a hybrid nanoparticle comprising a carborane = bearing pullulan nanogel and hydrophobized boron oxide nanoparticle (HBNGs) enabling the preparation of highly concentrated boron agents for efficient delivery. The HBNGs showed better anti-cancer effects on Colon26 cells than a clinically boron agent, L-BPA/fructose complex, by enhancing the accumulation and retention amount of the boron agent within cells in vitro. The accumulation of HBNGs in tumors, due to the enhanced permeation and retention effect, enabled the delivery of boron agents with high tumor selectivity, meeting clinical demands. Intravenous injection of boron neutron capture therapy (BNCT) using HBNGs decreased tumor volume without significant body weight loss, and no regrowth of tumor was observed three months after complete regression. The therapeutic efficacy of HBNGs was better than that of L-BPA/fructose complex. BNCT with HBNGs is a promising approach to cancer therapeutics. Hybrid nanoparticle comprising carborane bearing pullulan nanogel with hydrophobized boron oxide nanoparticle was developed for boron neutron capture therapy. [Display omitted] •Hybrid nanoparticle comprising of nanogel with boron oxide nanoparticle was prepared by supramolecular strategy.•Hybrid nanoparticles could efficiently induced cell death toward cancer cells by BNCT.•Tumor growth in tumor xenograft mice were significantly suppressed by BNCT using hybrid nanoparticles.